Together, these factors raise the cost of diligence and reduce the confidence that a fund can follow its normal investment cycle: deploy capital, improve the company, exit the position and return money to its limited partners.
The new-deal freeze follows a prolonged difficulty selling existing China holdings. The ten major firms recorded zero publicly disclosed complete divestments from mainland Chinese portfolio companies in 2025, marking a second consecutive year without such an exit.
That matters beyond individual investments. Private-equity firms depend on realizations to distribute cash to pension funds, sovereign investors, family offices and other limited partners. When assets remain locked up, investors may become less willing to commit to new China-focused funds or approve additional China exposure.
Earlier reporting also described U.S.-dollar fundraising for private-equity firms focused primarily on China as having nearly come to a halt. The result is a feedback loop: weak exits make fundraising harder, constrained fundraising reduces deployment capacity, and fewer new deals make it harder to maintain a deep local investment pipeline.
A zero in the Dealogic and PitchBook-based analysis is a disclosure measure, not a census of every transaction or every firm’s total China exposure. It does not prove that the ten firms sold nothing privately, made no minority investments, participated in secondaries or changed their portfolio companies internally.
The narrower conclusion is more defensible: no new mainland-China equity investments by this influential cohort were publicly disclosed in January–July 2026. That is still significant because large global firms are visible market participants and often serve as a signal of how international limited partners view a market’s risk-adjusted opportunity.
Nor does the finding describe the entire Chinese private-equity industry. Other data points show continued or recovering activity among domestic, RMB-funded and growth-oriented investors. A Bain report, for example, said Greater China deal volume and value increased for a second consecutive year in 2025, while exit value reached its highest level since 2022. The foreign buyout retreat therefore reflects the particular constraints facing globally funded firms rather than a uniform collapse across every category of Chinese capital.
The regional fundraising figures show why the China story matters beyond China. Asia-Pacific-focused private-equity funds raised $58 billion in 2025, excluding RMB-denominated vehicles—a 12-year low and a 37% decline from the prior year.
That does not mean every Asian market is equally impaired. But it does mean limited partners are demanding clearer evidence of realizations, liquidity and repeatable returns before committing capital. Markets that offer more predictable rules, easier capital movement or stronger exit channels can benefit as managers redirect attention elsewhere.
For China, the issue is increasingly one of investability: whether investors can reliably identify permitted opportunities, obtain approvals, move capital and realize returns. Lower valuations may create attractive entry points, but they do not by themselves solve regulatory or geopolitical risk.
Policy proposals intended to reassure foreign investors could improve confidence at the margin. But statements of intent alone are unlikely to restart large-scale foreign buyout activity while restrictions, enforcement uncertainty, sector limits, capital-repatriation concerns and weak exit liquidity remain unresolved.
The immediate lesson from the FT analysis is therefore not that global private equity has permanently abandoned China. It is that the normal investment case has broken down for a prominent group of firms. Until investors can see a credible path from entry to exit—and limited partners can see cash returned—the market may remain open in principle but closed in practice for many traditional cross-border buyout strategies.